Stem cell-derived retinal pigment epithelium cell therapy: Past and future directions.
Stem cell-derived retinal pigment epithelium cell therapy: Past and future directions.
复制标题
DOI：
10.3389/fcell.2023.1098406
复制
发表时间：
2023
影响因子：
5.5
通讯作者：
中科院分区：
文献类型：
--
作者：
The eyes are relatively immune privileged organs, making them ideal targets for stem cell therapy. Researchers have recently developed and described straightforward protocols for differentiating embryonic and induced pluripotent stem cells into retinal pigment epithelium (RPE), making diseases affecting the RPE, such as age-related macular degeneration (AMD), viable targets for stem cell therapy. With the advent of optical coherence tomography, microperimetry, and various other diagnostic technologies, the ability to document disease progression and monitor response to treatments such as stem cell therapy has been significantly enhanced in recent years. Previous phase I/II clinical trials have employed various cell origins, transplant methods, and surgical techniques to identify safe and efficacious methods of RPE transplantation, and many more are currently underway. Indeed, findings from these studies have been promising and future carefully devised clinical trials will continue to enhance our understanding of the most effective methods of RPE-based stem cell therapy, with the hope to eventually identify treatments for disabling and currently incurable retinal diseases. The purpose of this review is to briefly outline existing outcomes from initial clinical trials, review recent developments, and discuss future directions of clinical research involving stem-cell derived RPE cell transplantation for retinal disease.
影响因子：
2.4
作者：
Daniele, Elena;Ferrari, Barbara;Rassu, Nicolo;Ben-Nun, Joshua;Bosio, Lorenzo;Barbaro, Vanessa;Ferrari, Stefano;Ponzin, Diego
通讯作者：
Ponzin, Diego